SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

$WAGMI is a community-driven meme token built on the Solana blockchain, designed to bring positivity, unity, and humor into the crypto space. The project encourages community engagement through memes, social interaction, and token-based activities. It leverages Solana’s fast and low-cost infrastructure to allow for smooth on-chain interactions, such as token transfers, community games, and NFT integration. The goal is to foster a fun, inclusive ecosystem where holders feel they are part of a larger movement – "We Are Gonna Make It."

WAGMI

WAGMI is trending as community members express strong conviction and support, emphasizing the "We're All Gonna Make It" narrative. The community highlights its commitment and resilience, with some suggesting it could be the next SHIB. Discussions also revolve around WAGMI's presence on the Solana blockchain and potential integration within the broader crypto ecosystem.

Galaxy Digital, Inc. engages in digital assets and data center infrastructure, delivering solutions that accelerate progress in finance and artificial intelligence. It operates through the following segments: Digital Assets and Data Centers. The digital assets segment offers institutional access to trading, advisory, asset management, staking, self-custody, and tokenization technology. The Data Centers segment competes with a range of infrastructure providers that are building or repurposing facilities to support the rapidly growing demand for AI and compute-intensive workloads. The company was founded by Michael Novogratz in 2018 and is headquartered in New York, NY.

Galaxy Digital Inc. - Ordinary Shares - Class A

GLXY is trending as investors anticipate a potentially positive earnings report, focusing on revenue beats and forward guidance related to AI data centers. Community members are actively discussing the potential impact of the earnings on the stock price and whether news related to ERCOT approval will be released. The stock is also garnering attention due to its positioning in both the crypto and AI infrastructure sectors.

GSI Technology, Inc. engages in the design, development and marketing of memory products primarily for the networking, and telecommunications markets. Its product includes Static Random Access Memory, or SRAM, which incorporated in networking and telecommunications equipment, such as routers, switches, wide area network infrastructure equipment, wireless base stations and network access equipment. It also offers services to the ongoing needs of the military, industrial, test and measurement equipment, automotive and medical markets for SRAMs .The company was founded by Lee-Lean Shu and Robert Yau in March 1995 and is headquartered in Sunnyvale, CA.

GSI Technology Inc

$GSIT is trending following news of its Compute-In-Memory APU achieving GPU-class AI performance with significantly lower energy consumption, sparking excitement about its potential to disrupt the AI semiconductor industry. Community members are discussing the possibility of a multi-day run and a potential partnership or acquisition by a larger player like $NVDA. Some traders are also eyeing the $17.50 resistance level, considering strategies around potential breakouts or reversals.

UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health and wellness care, serving the broad health care marketplace including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the healthcare industry. The OptumRx segment offers pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Eden Prairie, MN.

Unitedhealth Group Inc

UNH is trending as investors monitor the broader healthcare sector, particularly in anticipation of upcoming earnings reports from sector peers like ELV which may signal the direction of UNH. Community discussions revolve around potential impacts from government shutdowns, ACA subsidies, and the possibility of increased institutional investment following recent filings. Some traders are also expressing concern over regulatory probes and mixed opinions on the stock's short-term and long-term outlook.

General Motors Co. engages in the designing, manufacturing, and selling of trucks, crossovers, cars, and automobile parts, and in providing software-enabled services and subscriptions. It operates through the following segments: GMNA, GMI, Cruise, and GM Financial. The company was founded by William C. Durant on September 16, 1908 and is headquartered in Detroit, MI.

General Motors Company

General Motors is trending following its Q3 earnings report, which included an EPS and revenue beat, as well as increased guidance. Community members are focused on the company's free cash flow and full-year EBIT outlook. Broader discussion centers on how GM is managing EV production and navigating the impact of tariffs.

Solana is a highly functional open source project that banks on blockchain technology’s permissionless nature to provide decentralized finance (DeFi) solutions. It is a layer 1 network that offers fast speeds and affordable costs. While the idea and initial work on the project began in 2017, Solana was officially launched in March 2020 by the Solana Foundation with headquarters in Geneva, Switzerland.

Solana

Solana is trending as the community discusses potential growth and solid volume, while some traders point to a native perpetual DEX blueprint. Mentions of Phantom Wallet gems, like $MOONROCK and $CUTIE, suggest interest in new Solana-based projects. Community members express bullish sentiment, with some anticipating a significant rise and highlighting staking opportunities.

GIGA is a meme token deployed on the Solana blockchain intended to honor the legend Ernest Khalimov the original “Gigachad”, by utilizing the strength of memes and “Chad” energy.  GIGA is a community run project.

GigaChad

GigaChad is trending as community members express strong bullish sentiment, highlighting its potential for significant gains and drawing comparisons to other successful meme coins like SPX. The community emphasizes GigaChad's strong cultural presence and active engagement, with some pointing to its association with Giga Fitness as a unique value proposition. The recent price action has sparked discussions about potential breakout points and future price targets, with many expressing conviction in its long-term potential.

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

SLV is trending as silver prices surge, driven by a potential supply squeeze and increasing demand. The community is debating whether this rally is sustainable, with some pointing to manipulation and historical patterns, while others cite strong physical demand and potential for much higher prices. Discussions also include the impact of a weaker dollar and potential safe-haven buying amid broader market concerns.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

CADL is trending due to positive analyst coverage and community excitement around potential breakthroughs in cancer immunotherapy, particularly for prostate cancer. Community members are discussing the company's financial positioning, potential partnerships, and the upcoming data releases for CAN-3110. Some investors believe CADL is significantly undervalued, with potential for substantial returns based on its clinical pipeline and market opportunities.

AlphaVest Acquisition Corp. is a blank check company, which engages in effecting a merger, stock exchange, asset acquisition, stock purchase, and reorganization or similar business combination. The company was founded on January 14, 2022 and is headquartered in New York, NY.

AlphaVest Acquisition Corp

AlphaVest Acquisition Corp ($ATMV) is trending with significant volatility and trading halts, fueled by discussions around a potential merger; some speculate it could run much higher due to its low float. The community is closely watching for breakouts and potential short squeezes, while also cautioning about potential risks associated with SPACs and high volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of Revolution Medicines, Disc Medicine, and Regeneron Pharmaceuticals rose in after-hours trading on Thursday after the U.S. Food and Drug Administration (FDA) announced the first group of drugs selected for expedited review under its new National Priority Voucher pilot program.In after-hours trading on Thursday,&nbsp;<a href="https://stocktwits.com/symbol/RVMD">Revolution Medicines</a> jumped 9%,&nbsp;<a href="https://stocktwits.com/symbol/IRON">Disc Medicine</a> surged 17%, and&nbsp;<a href="https://stocktwits.com/symbol/REGN">Regeneron Pharmaceuticals</a> edged up 0.1%.FDA Names 9 Drugs For Accelerated ReviewThe FDA said nine products have been chosen for the fast-track review process, which shortens decision timelines from the usual 10–12 months to just one or two months once a complete application is filed.The selected drugs include Merck KGaA’s fertility treatment Pergoveris, Sanofi’s Type 1 diabetes therapy teplizumab, Regeneron’s gene therapy DB-OTO for congenital deafness, and ketamine for domestic manufacturing of a general anesthetic.&nbsp;Also on the list are Revolution Medicines’ RMC-6236 for pancreatic cancer, Disc Medicine’s bitopertin for porphyria, Achieve Life Sciences’ cytisinicline for nicotine vaping addiction, Dompe’s cenegermin-bkbj for blindness, and Augmentin XR for domestic manufacturing of a common antibiotic.FDA Commissioner Highlights Expedited Review EffortFDA Commissioner Marty Makary said the initiative could shorten FDA decision times from a year to "a matter of weeks” by moving promising or high-impact therapies to the front of the review line.Makary said some of the drugs selected for vouchers, including one that uses ketamine as a general anesthetic, will be manufactured in the United States. He described Regeneron’s DB-OTO, a gene therapy for congenital deafness, as “an exciting treatment,” noting that “some of these kids got normal hearing from this amazing treatment.”He added that this is just the first round of vouchers, with additional selections expected in the coming weeks.How Stocktwits Traders Reacted To FDA’s Fast-Track ListOn Stocktwits, retail sentiment toward Revolution Medicines was ‘extremely bullish’ with ‘extremely high’ message volume, while Disc Medicine saw ‘neutral’ sentiment amid similarly ‘extremely high’ activity, and Regeneron registered ‘neutral’ sentiment with ‘normal’ engagement levels.One&nbsp; user said they expect Regeneron shares to climb steadily, projecting the stock could reach the $800-$900 range within two years.&nbsp;<stembedurl>https://stocktwits.com/Iwannagofast1/message/632653980</stembedurl>Another bullish trader suggested Revolution Medicines could be an attractive takeover candidate, potentially fetching twice its current value.<stembedurl>https://stocktwits.com/ChessGM/message/632555600</stembedurl>So far this year, Revolution Medicines shares have gained 14%, Disc Medicine is up 17%, while Regeneron has declined 20%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the FDA (United States Food and Drug Administration) logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Revolution Medicines, Disc Medicine, Regeneron Stocks Jump After-Hours As FDA Fast-Tracks 9 Drugs Under New Review Program

The FDA’s new National Priority Voucher pilot helps with faster drug reviews, cutting timelines from nearly a year to weeks.

Equity

Raymond James bullish on biotech firms on favorable valuation

Investing.com -- Raymond James started coverage on biotechnology companies, rating Avidity Biosciences and Disc Medicine at Strong Buy and assigning Outperform ratings to Dyne Therapeutics, Tectonic Therapeutic, and Wave Life Sciences (NASDAQ:WVE), pointing to a sector-wide opportunity amid “suppressed valuations.”

Disc Medicine (NASDAQ:IRON) Given "Outperform" Rating at Wedbush

Wedbush reaffirmed their outperform rating on shares of Disc Medicine (NASDAQ:IRON - Free Report) in a report issued on Monday morning, RTT News reports. Wedbush currently has a $43.00 price...

FY2024 Earnings Estimate for Disc Medicine, Inc. Issued By Wedbush (NASDAQ:IRON)

Disc Medicine, Inc. (NASDAQ:IRON - Free Report) - Wedbush boosted their FY2024 earnings per share (EPS) estimates for Disc Medicine in a report released on Monday, April 1st. Wedbush analyst D...

Leerink Partnrs Comments on Disc Medicine, Inc.'s Q2 2024 Earnings (NASDAQ:IRON)

Disc Medicine, Inc. (NASDAQ:IRON - Free Report) - Stock analysts at Leerink Partnrs reduced their Q2 2024 earnings per share estimates for shares of Disc Medicine in a report issued on Monday, April...

Raymond James Reiterates "Outperform" Rating for Disc Medicine (NASDAQ:IRON)

Disc Medicine (NASDAQ:IRON - Get Free Report)s stock had its "outperform" rating reaffirmed by analysts at Raymond James in a report issued on Monday, Marketbeat Ratings reports. They...

Analysts Offer Insights on Healthcare Companies: Assembly Biosciences (ASMB), Natera (NTRA) and Disc Medicine (IRON)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Assembly Biosciences (ASMB Research Report), Nater...

Disc Medicine price target lowered by $30 at BMO Capital, here's why

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Disc Medicine price target lowered by $33 at Stifel, here's why

Disc Medicine (IRON, $34.31) RSI Indicator left the oversold zone on April 01, 2024

This is a signal that IRON's price could be shifting from a downtrend to an uptrend. Traders may consider buying the stock or exploring call options...

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of treatments for hematologic diseases. It assembles a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. The company was founded in October 2017 and is headquartered in Watertown, MA.

Disc Medicine Inc

Will Netflix ($NFLX) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Netflix Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

Current Price	$87.17
Prev Close	$89.94
Open	$90.19
Dividend Yield	0.00%
50-Day Moving Average	$64.24
Beta	1.03
Avg. Volume	363,015.52
PE Ratio	-19.48

52-Week High	$95.95
52-Week Low	$30.82
Market Capitalization	$3.03B
EPS (Annual)	-$3.96
Price to Book	4.92
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

IRON
Disc Medicine Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest IRON News

IRONDisc Medicine Inc